TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02712346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One inactive pill daily for twelve weeks
Study: NCT02362815

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Intervention consists in allowing drinks during labour
Study: NCT02769923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Westpharma ID adapter
Description: device used for administering intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Star ID syringe
Description: device used for administering intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCG NS
Description: syringe used for administering intradermal injection
Study: NCT01131975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study: NCT00374140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Description: 10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
Study: NCT03999996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Description: TDV subcutaneous injection
Study: NCT03220971

Intervention type: OTHER
Intervention: lipoprotein and apolipoproteins
Description: To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases

Intervention type: OTHER
Intervention: lipoprotein and apolipoproteins
Description: To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
Study: NCT03999996

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) subcutaneous injection
Study: NCT02847247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRE
Description: Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
Study: NCT04694443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)
Description: Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard in-office medical care
Description: Non-pharmacological and pharmacological treatment provided in-office visits
Study: NCT03816696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
Study: NCT00617734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux ®)
Description: IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
Study: NCT01004952

Intervention type: BEHAVIORAL
Intervention: screening questionnaire
Description: Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
Study: NCT04503070

Intervention type: BEHAVIORAL
Intervention: Motion capture participant
Description: Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort
Study: NCT01648712

Intervention type: DEVICE
Group type: OTHER
Intervention: Balance surface, Carmeda heparin-coated surface
Description: This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit

Intervention type: DEVICE
Group type: OTHER
Intervention: non -heparin extracorporeal pediatric device for operation
Description: The carmeda arm group received like intervention the Carmeda circuit
Study: NCT03694561

Intervention type: OTHER
Intervention: Observational
Description: This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
Study: NCT01943643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multislice CT angiography
Description: Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
Study: NCT01847521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin, Quercetin and Rutin combined in a capsule
Study: NCT02488577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal minimally invasive total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal minimally invasive locoregional resection
Study: NCT01402752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood flow to the tracheo-bronchial mucosa
Description: Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
Study: NCT04041713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rett-T
Description: antioxidant cocktail

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03107481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone 1mg IV
Study: NCT00647517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultracet
Description: For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.
Study: NCT03660462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FePO4 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HiFePO4 1 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HiFePO4 2 fortified rice test meal
Description: Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
Study: NCT03201068

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Probiotic supplement capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT03064529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
Study: NCT02173080

Intervention type: OTHER
Intervention: PLD-Q
Description: polycystic liver disease questionnaire

Intervention type: OTHER
Intervention: PLD-Q
Description: polycystic liver disease questionnaire
Study: NCT02470897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo urethral-sparing IMRT planning

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo urethral-sparing IMRT planning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Undergo moderate dose SBRT with SIB

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Undergo uniform dose SBRT
Study: NCT03804528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines).
Study: NCT03433651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Subjects will take by mouth 5 grams a day of creatine monohydrate powder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take by mouth 5 grams a day of placebo powder.
Study: NCT04049032

Intervention type: BEHAVIORAL
Intervention: In-Person Perinatal OUD Treatment
Description: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.

Intervention type: BEHAVIORAL
Intervention: Perinatal OUD Treatment via Telemedicine
Description: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
Study: NCT04500158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine with 1:100,000 epi
Study: NCT03064802

Intervention type: DEVICE
Intervention: BioBurst Fluid, Burst Allograft
Description: BioBurst Fluid or Burst Allograft used to augment spinal fusion
Study: NCT03396809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctal plug
Description: Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
Study: NCT01049295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oil fish
Description: Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn oil pearls
Description: corn oil pearls 3 times a day
Study: NCT01415531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
Study: NCT02008396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
Study: NCT06700668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Powered Knee
Description: MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
Study: NCT06704438

Intervention type: DIAGNOSTIC_TEST
Intervention: D-Lactate
Description: D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: D-Lactate
Description: D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
Study: NCT01415531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-match placebo
Study: NCT06705608

Intervention type: DRUG
Intervention: Fingolimod
Description: patients who received fingolimod for treating RRMS

Intervention type: DRUG
Intervention: Natalizumab
Description: patients who received natalizumab for treating RRMS (active comparator)

Intervention type: DRUG
Intervention: Dimethyl fumarate (DMF)
Description: patients who received dimethyl fumarate for treating RRMS (active comparator)

Intervention type: DRUG
Intervention: Alemtuzumab
Description: patients who received alemtuzumab for treating RRMS (active comparator)

Intervention type: DRUG
Intervention: Teriflunomide
Description: patients who received teriflunomide for treating RRMS (active comparator)
Study: NCT02633059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00684866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: (a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: (a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Study: NCT04449913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 days intensive meditation retreat
Description: The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting for a 10 days intensive meditation retreat
Description: At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
Study: NCT02539823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 400 mg
Description: Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 800 mg
Description: Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
Study: NCT02191462

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 100mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 300mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen 1000mg
Study: NCT01962792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01733420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine pulpotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: White MTA pulpotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempophore pulpotomy
Study: NCT01198886

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Successful Aging Program
Description: Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-Nutrition Program
Description: Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
Study: NCT03449511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ginger aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba aromatherapy
Description: Three sniffs of aromatherapy inhaler four times daily for seven days.